Overview
Human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus (KSHV), is a significant pathogen associated with the development of Kaposi's sarcoma (KS) and other lymphoproliferative disorders. The virus establishes lifelong latency in the host, often remaining asymptomatic until specific triggers, such as immunosuppression, activate its replication and lead to clinical manifestations. Understanding the pathophysiology, epidemiology, clinical presentation, diagnosis, and management of HHV-8 infection is crucial for effective patient care, particularly in high-risk populations. This guideline synthesizes current evidence to provide clinicians with a comprehensive overview of HHV-8 skin infection, focusing on its clinical implications.
Pathophysiology
The pathophysiology of HHV-8 infection involves complex interactions between viral mechanisms and host cellular responses. One critical aspect is the robust induction of cyclooxygenase-2 (COX-2) expression by HHV-8, which plays a pivotal role in sustaining latent viral gene expression, particularly the ORF73 gene. Studies using human microvascular endothelial cells (HMVEC-d) and human foreskin fibroblasts (HFF) have demonstrated that COX-2 expression is essential for maintaining the latent state of HHV-8 [PMID:16775340]. This mechanism underscores the importance of anti-inflammatory pathways in viral latency and suggests potential therapeutic targets.
Furthermore, experimental models have elucidated the progression of HHV-8 infection in vivo. Injection of HHV-8 into human skin grafted onto severe combined immunodeficiency (SCID) mice resulted in the development of lesions resembling Kaposi's sarcoma. These lesions exhibited characteristic features such as angiogenesis and the presence of spindle-shaped cells, which are latently infected with HHV-8 [PMID:11390203]. This animal model provides valuable insights into the natural history of HHV-8 infection and its transformation into clinically observable disease states, highlighting the role of viral persistence and cellular changes in lesion formation.
Epidemiology
The global distribution and prevalence of HHV-8 infection vary significantly across different populations, influenced by factors such as geographic location, immunosuppression status, and demographic characteristics. A notable study conducted among 140 pregnant women in Geneva, Switzerland, reported a seroprevalence of 7.9% for HHV-8 [PMID:20569167]. Notably, within this cohort, the African subpopulation exhibited a markedly higher seroprevalence rate of 33.3%, indicating a strong association between geographic origin and infection risk. This disparity underscores the importance of considering demographic factors in assessing HHV-8 exposure and risk.
Additionally, the study highlighted that seropositive women were more likely to be ≥32 years old compared to seronegative women (81.8% vs. 43%, p = 0.023) [PMID:20569167]. This age-related trend suggests that older individuals may have had prolonged exposure or cumulative risk factors that contribute to higher seroprevalence. Understanding these epidemiological patterns is crucial for targeted screening and preventive strategies, particularly in high-risk groups.
Clinical Presentation
The clinical manifestations of HHV-8 infection primarily manifest as Kaposi's sarcoma, characterized by distinctive skin lesions. These lesions are hallmarked by angiogenesis and the presence of spindle-shaped cells, which are hallmarks of viral latency and cellular transformation [PMID:11390203]. Clinically, these lesions typically appear as painless, violaceous plaques or nodules, often found on the lower extremities but can occur anywhere on the skin. The progression of these lesions can vary, from indolent to aggressive forms, depending on the host's immune status and other co-factors.
In addition to cutaneous manifestations, HHV-8 can also lead to extracutaneous involvement, including lymphedema, lymphadenopathy, and visceral organ involvement, particularly in immunocompromised individuals. The variability in clinical presentation underscores the need for a thorough clinical evaluation, including detailed patient history and physical examination, to identify early signs of HHV-8-related disease. Early detection and intervention are critical for managing the progression of Kaposi's sarcoma and mitigating its impact on patient outcomes.
Diagnosis
Diagnosing HHV-8 infection and its associated conditions, such as Kaposi's sarcoma, relies on a combination of clinical assessment and laboratory testing. The identification of latently infected spindle-shaped cells in biopsy specimens is crucial for confirming the diagnosis of Kaposi's sarcoma [PMID:11390203]. Histopathological examination often reveals characteristic features such as the presence of HHV-8 encoded proteins, including LANA-1 (latency-associated nuclear antigen-1), which can be detected using immunohistochemistry.
Serological testing for HHV-8 antibodies is another essential diagnostic tool, although it primarily indicates past exposure rather than active infection. Elevated antibody titers can support the diagnosis, especially in conjunction with clinical findings. Molecular techniques, such as polymerase chain reaction (PCR), can detect viral DNA in tissue samples, providing definitive evidence of active HHV-8 infection. These diagnostic approaches collectively enable clinicians to accurately diagnose HHV-8-related conditions and tailor appropriate management strategies based on the stage and extent of the disease.
Management
The management of HHV-8 infection and its complications, particularly Kaposi's sarcoma, involves a multifaceted approach aimed at controlling both the viral burden and the clinical manifestations of the disease. Anti-inflammatory treatments, specifically COX-2 inhibitors, have shown promise in reducing latent viral gene expression and promoter activity, suggesting a potential role in managing viral latency [PMID:16775340]. While these findings are promising, their clinical application requires further investigation to establish efficacy and safety profiles in diverse patient populations.
For active Kaposi's sarcoma, treatment strategies often include systemic therapies such as antiretroviral therapy (ART) in HIV-positive patients to bolster immune function, chemotherapy, and targeted therapies like liposomal doxorubicin or interferon alfa. In cases where visceral involvement is significant, more aggressive interventions, including surgical resection or radiation therapy, may be necessary. Supportive care measures, including wound management and pain control, are also integral to improving quality of life for patients with advanced disease.
Given the complexity of HHV-8-related conditions, a multidisciplinary approach involving dermatologists, oncologists, immunologists, and infectious disease specialists is often required to optimize patient outcomes. Regular monitoring and tailored treatment plans based on disease progression and patient-specific factors are essential components of effective management.
Key Recommendations
These recommendations aim to guide clinicians in effectively managing HHV-8 infection and its associated conditions, emphasizing early detection and personalized treatment approaches to improve patient outcomes.
References
1 Sharma-Walia N, Raghu H, Sadagopan S, Sivakumar R, Veettil MV, Naranatt PP et al.. Cyclooxygenase 2 induced by Kaposi's sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression. Journal of virology 2006. link 2 de Tejada BM, Steffen I, Cantero P, Posfay-Barbe KM, Irion O, Hirschel B et al.. Human herpes virus type 8 seroprevalence in pregnant women in Geneva, Switzerland. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2011. link 3 Foreman KE, Friborg J, Chandran B, Katano H, Sata T, Mercader M et al.. Injection of human herpesvirus-8 in human skin engrafted on SCID mice induces Kaposi's sarcoma-like lesions. Journal of dermatological science 2001. link00087-1)